Compare DH & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DH | AARD |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.9M | 85.7M |
| IPO Year | 2021 | N/A |
| Metric | DH | AARD |
|---|---|---|
| Price | $0.98 | $4.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $3.08 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 320.8K | 164.9K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,521,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $3.35 |
| 52 Week High | $4.70 | $17.94 |
| Indicator | DH | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 38.23 |
| Support Level | $0.93 | $3.35 |
| Resistance Level | $1.10 | $4.39 |
| Average True Range (ATR) | 0.07 | 0.57 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 87.36 | 6.66 |
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.